I care very little about the short term action. The company will be made or not on the results of human trials. Regardless of the price today, if they are successful in a Phase I/IIa next year the stock will head towards the $10B mark well before the drug is approved or does a dime in sales (see ICPT, PCYC, VRUS). If not successful then it goes equally dramatically in the other direction. But there are a lot of potential catalysts between here and trials, so assuming the company reasonably executes on the timeline given I suspect the price will be significantly higher entering those trials.